ASX healthcare stocks look to partner up to fund drug development
ASX healthcare companies are increasingly looking to tap into licensing and partnering deals to fund...
ASX healthcare companies are increasingly looking to tap into licensing and partnering deals to fund...
Special Report: Prescient Therapeutics has entered an important stage in development of its lead cancer...
Special Report: Clinical-stage oncology company Prescient Therapeutics has reached a key milestone in the Phase 2a...
Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech...
Prescient Therapeutics (ASX:PTX) is at the forefront of this approach with PTX-100, a small molecule which...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.